孕12+0至15+6周母体血流动力学参数对子痫前期的预测
这项前瞻性病例对照研究纳入743例中国单胎妊娠孕妇,比较后续发生子痫前期(PE)与未发生者的母体血流动力学参数。早产PE和任何时点PE孕妇的全身血管阻力(SVR)升高、心输出量(CO)降低,但在FMF三联试验基础上加入CO或SVR并未改善筛查性能。
要点
- 早产PE和任何时点PE孕妇在孕12+0至15+6周时SVR升高、CO降低。
- 心率在各组间无显著差异。
- 在FMF三联试验中加入CO或SVR未提高PE筛查检出率。
核心结论
- 早产PE或任何时点PE孕妇在临床表现出现前已存在SVR升高和CO降低,可能提示心血管适应不良。
- 孕12+0至15+6周评估母体血流动力学参数未增强对这些参数的PE筛查性能。
- FMF三联试验在预测PE方面仍优于其他生物标志物组合。
研究设计与样本
- 前瞻性病例对照研究,纳入2020年2月至2023年2月在中国单胎妊娠孕妇。
- 孕妇在孕11+0至13+6周接受FMF三联试验筛查,高风险(≥1:100)与低风险(<1:100)按1:1匹配。
- 共分析743例,其中39例(5.2%)后续发生PE,包括29例(3.9%)早产PE和10例(1.3%)足月PE。
- 在孕12+0至15+6周进行二维经胸超声心动图评估母体血流动力学参数。
主要发现
- 早产PE和任何时点PE组的平均log10 SVR MoM显著高于未受影响妊娠。
- 早产PE和任何时点PE组的平均log10 SV MoM和log10 CO MoM显著低于未受影响妊娠。
- 平均log10 HR MoM在研究组间无显著差异。
- 在早产PE和任何时点PE中,平均log10 CO MoM和log10 SVR MoM与分娩时孕周无显著相关性。
- 在FMF三联试验中加入CO或SVR或用CO和SVR替代MAP,预测早产PE和任何时点PE的AUC相同或更大,但ΔAUC无显著差异;在固定10%假阳性率下未改善检出率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the maternal hemodynamic profile at 12 + 0 to 15 + 6 weeks' gestation in women who subsequently developed pre-eclampsia (PE) and those who did not, and to assess the screening performance of maternal hemodynamic parameters for PE in combination with the Fetal Medicine Foundation (FMF) triple test, including maternal factors (MF), mean arterial pressure (MAP), uterine artery pulsatility index and placental growth factor. METHODS: This was a prospective case-control study involving Chinese women with a singleton pregnancy who underwent preterm PE screening at 11 + 0 to 13 + 6 weeks' gestation using the FMF triple test, between February 2020 and February 2023. Women identified as being at high risk (≥ 1:100) for preterm PE by the FMF triple test were matched 1:1 with women identified as low risk (< 1:100) for maternal age ± 3 years, maternal weight ± 5 kg and date of screening ± 14 days. Two-dimensional transthoracic echocardiography was performed at 12 + 0 to 15 + 6 weeks to evaluate maternal hemodynamic parameters (heart rate (HR), stroke volume (SV), cardiac output (CO) and systemic vascular resistance (SVR)). Maternal hemodynamic parameters were expressed as multiples of the median (MoM) values, determined by linear regression models to adjust for gestational age (GA) and MF. The distribution of log10 MoM values of maternal hemodynamic parameters in cases of PE and unaffected pregnancies, and the association between these hemodynamic parameters and GA at delivery, were assessed. The risks of preterm PE (delivery before 37 weeks) and any-onset PE (delivery at any time) were reassessed using Bayes' theorem after maternal hemodynamic parameters were added to the FMF triple test. The screening performance for preterm PE and any-onset PE was determined by the area under the receiver-operating-characteristics curve (AUC) and detection rate at a 10% fixed false-positive rate (FPR). Differences in AUC (ΔAUC) were assessed using DeLong's test. RESULTS: A total of 743 cases were analyzed, of whom 39 (5.2%) subsequently developed PE, including 29 (3.9%) cases of preterm PE and 10 (1.3%) cases of term PE. Mean log10 SVR MoM was significantly higher in cases of preterm PE and any-onset PE compared with unaffected pregnancies. Mean log10 SV MoM and log10 CO MoM were significantly lower in cases of preterm PE and any-onset PE compared with unaffected pregnancies. Mean log10 HR MoM was not significantly different between the study groups. Mean log10 CO MoM and log10 SVR MoM were not significantly correlated with GA at delivery in preterm PE and any-onset PE. For the prediction of preterm PE and any-onset PE, adding CO or SVR or replacing MAP with CO and SVR in the FMF triple test achieved an identical or greater AUC compared with the FMF triple test, but ΔAUC was not significantly different. In addition, adding CO or SVR or replacing MAP by CO and SVR in the FMF triple test did not improve the detection rate for preterm PE and any-onset PE at a fixed FPR of 10%. CONCLUSIONS: Women with preterm PE or any-onset PE exhibited increased SVR and decreased CO before the clinical manifestations of PE became apparent. These changes may serve as early indicators of cardiovascular maladaptation. However, assessment of maternal hemodynamics at 12 + 0 to 15 + 6 weeks does not enhance the screening performance for preterm PE and any-onset PE of these parameters. The FMF triple test remains superior to other biomarker combinations for predicting PE. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Wang X, Sahota DS, Wong L, et al. Prediction of pre-eclampsia using maternal hemodynamic parameters at 12 + 0 to 15 + 6 weeks. Ultrasound Obstet Gynecol. 2025. PMID: 39825806. doi:10.1002/uog.29177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。